PureTech Health plans a $100m capital return to shareholders through a tender offer, targeting 14% of market cap.

PureTech Health Plc, a clinical-stage biotherapeutics company, plans a $100m capital return to shareholders through a tender offer, targeting 14% of market capitalization. The proposal follows $293m gross proceeds from Karuna stake. Subject to market conditions and shareholder approval, the tender offer will launch post April 2024 results. Any remaining funds will be distributed as a special dividend.